Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華控康泰集團有限公司
Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)


(Stock Code: 1312)

VOLUNTARY ANNOUNCEMENT
CHANGE IN SHAREHOLDING STRUCTURE OF THE CONTROLLING SHAREHOLDER


This announcement is made by Kontafarma China Holdings Limited (the "**Company**") on a voluntary basis.

The Company has recently been forwarded by Shanxi Construction Investment Group Co., Ltd.* (山西建設投資集團有限公司) ("**Shanxi Construction**") the "Notice from Shanxi Government Commission Regarding the Transfer of State-owned Equity Interest in Relevant Enterprise Held by Shanxi State-owned Capital Operation Co., Ltd. to Shanxi Government Commission" (Jin Guo Zi Chan Quan [2025] No. 75). Pursuant to the document, the People's Government of Shanxi Province has resolved to transfer the 52.44% equity interest in Shanxi Construction held by Shanxi State-owned Capital Operation Co., Ltd.* (山西省國有資本運營有限公司) ("**State-owned Capital Operation Co.**") to be directly held by the State-owned Assets Supervision and Administration Commission of Shan Xi Provincial Government ("**Shanxi Government Commission**") and transfer the 90% equity interest in Shanxi Transportation Holdings Group Co., Ltd.* (山西交通控股集團有限公司) ("**Shanxi Transportation**") held by State-owned Capital Operation Co. to be directly held by Shanxi Government Commission (the "**Transfer**"). Prior to and following the Transfer, Waranty Assets Management (HK) Limited remains the direct controlling shareholder of the Company, while Shanxi Government Commission remains the ultimate beneficial owner of the Company. Currently, the aforementioned matter is pending completion of the business registration change procedures.

The shareholding structure of the Company before the Transfer is shown in the diagram as follows:



The shareholding structure of the Company after the Transfer is shown in the diagram as follows:



The Transfer will not result in changes to the Company's ultimate beneficial owners, direct controlling shareholders, or their shareholding percentages, nor will it affect the stability of controlling structure of the Company. It will not adversely affect the normal production and operation, or sustainable development of the Company, and will not prejudice the interests of the Company or its minority shareholders.

By order of the Board of
Kontafarma China Holdings Limited
Wang Feifei
Chairman

Hong Kong, 5 December 2025

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Wang Feifei (Chairman and President), Ms. Guo Zixiu (Financial Controller) and Mr. Liu Jiankun; one non-executive Director, namely Mr. Huang Yu; and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.

* *For identification purpose only*